 
                    
                Cellromax Science Co., Ltd.
Develops health foods, derma-cosmetics, and OTC drugs for pharmacies and online channels.
471820 | KO
Overview
Corporate Details
- ISIN(s):
- KR7471820001
- LEI:
- Country:
- South Korea
- Address:
- 경기도 용인시 기흥구 구성로 357 D동 710호 (청덕동, 용인테크노밸리), 용인시
- Website:
- https://www.cellromax.kr/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Cellromax Science Co., Ltd. is a KOSDAQ-listed company specializing in the development, manufacturing, and distribution of health-oriented products. Its primary business divisions include health functional foods, derma-cosmetics, and over-the-counter (OTC) pharmaceuticals. The company focuses on creating differentiated products through dedicated research, using carefully selected natural-origin raw materials and optimal formulation science. Key product features include specialized prescriptions and user-friendly formulation technology. Cellromax Science distributes its products through pharmacies and direct-to-consumer online channels. The company was formerly known as Pharmacist & Health Co., Ltd. and rebranded in 2021.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-12 00:00 | Notice of Dividend Amount 현금ㆍ현물배당결정              (분기배당) | Korean | 8.1 KB | ||
| 2025-09-12 00:00 | Notice of Dividend Amount 중간(분기)배당을위한주주명부폐쇄(기준일)결정               | Korean | 5.5 KB | ||
| 2025-09-01 00:00 | Share Issue/Capital Change 감자완료               | Korean | 8.9 KB | ||
| 2025-08-27 00:00 | Interim Report 반기보고서 (2025.06) | Korean | 1.2 MB | ||
| 2025-08-13 00:00 | Share Issue/Capital Change [기재정정]주요사항보고서(감자결정) | Korean | 22.5 KB | ||
| 2025-08-12 00:00 | Share Issue/Capital Change [기재정정]전환청구권행사              (제1회차) | Korean | 11.8 KB | ||
| 2025-07-23 00:00 | Post-Annual General Meeting Information 임시주주총회결과               | Korean | 5.6 KB | ||
| 2025-07-22 00:00 | Share Issue/Capital Change 전환청구권행사              (제1회차) | Korean | 8.7 KB | ||
| 2025-07-16 00:00 | Major Shareholding Notification 임원ㆍ주요주주특정증권등소유상황보고서 | Korean | 25.0 KB | ||
| 2025-07-10 00:00 | Major Shareholding Notification 임원ㆍ주요주주특정증권등소유상황보고서 | Korean | 24.2 KB | ||
| 2025-07-09 00:00 | Notice of Dividend Amount 현금ㆍ현물배당결정              (분기배당) | Korean | 8.8 KB | ||
| 2025-07-09 00:00 | Transaction in Own Shares 주요사항보고서(자기주식취득신탁계약체결결정) | Korean | 35.5 KB | ||
| 2025-07-08 00:00 | Pre-Annual General Meeting Information 주주총회소집공고 | Korean | 58.7 KB | ||
| 2025-07-07 00:00 | Regulatory News Service 신탁계약해지결과보고서 | Korean | 35.1 KB | ||
| 2025-06-13 00:00 | Notice of Dividend Amount 수시공시의무관련사항(공정공시)              (주주가치 제고를 위한 주주환원계획 수립) | Korean | 8.8 KB | 
Automate Your Workflow. Get a real-time feed of all Cellromax Science Co., Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cellromax Science Co., Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cellromax Science Co., Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value | 
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
 
                                        
                                     
                                        
                                     
                                        
                                     
                                        
                                     
                                        
                                     
                                        
                                     
                                        
                                     
                                        
                                    